Report of ten years' activity in an Alzheimer's disease assessment unit

Aging Clinical and Experimental Research

Volumn 21, Issue 4-5, 2009, Pages 365-368

  Sinforiani, Elena ^a   Zucchella, Chiara ^a   Pasotti, Chiara ^a   Bartolo, Michelangelo ^a   Nappi, Giuseppe ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Clinical management

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHIATRY; OUTCOME ASSESSMENT; OUTPATIENT; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 73849138894     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324930     Document Type: Article

References (26)

1. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochraine Database Syst Rev 2006; 1: CD005593.
2. Birks J, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CDOO1190.
3. Hoklyn J, Mohany S, Yaffe K. Efficacy of Cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's Disease. A meta-analysis. JAMA 2003; 299: 210-216
4. Grimmer T, Kurz A. Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review. Drugs Aging 2006; 23: 957-967 (Pubitemid 44936062)
5. Caltagirone C, Bianchetti A, Di Luca M et al. Guidelines for the treatment of Alzheimer's Disease from the Italian Association of Psychogeriatrics. Drugs Aging 2005; 22 (Suppl): 1-37.
6. Waldemar G, Dubois B, Emre M et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guidelines. Eur J Neurol 2007; 14: 1-26.
7. Wild R, Pettit T, Bums A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003; 3: CD003672.
8. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease N Engl J Med 2004; 35: 2509-2518
9. Poewe W, Wolters E, Emre M et al. EXPRESS Investigators. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006; 21: 456-461
10. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006; 1: CD004747.
11. Courtney C, Farrell D, Gray R et al. AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease. Lancet 2004; 383: 2105-2115
12. National Council of Clinical Excellence. Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine guidance. November 17; 2006.
13. Getsios D, Migliaccio-Walle K, Caro J. NICE cost-effectiveness appraisal of Cholinesterase inihibitors: was the right question posed? Were the best tools used? Pharmacoeconomics 2007; 25: 997-1006.
14. Lyle S, Grizzell M, Willmost S, Benbow S, Clark M, Jolley D. Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned. Dementia Geriatr Cogn Disord 2008; 25: 225-231
15. Raschetti R., Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 2005; 61: 361-368 (Pubitemid 41569310)
16. Bellelli G, Lucchi E, Minicuci N et al. Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study. Aging Clin Exp Res 2005; 17: 54-61.
17. Sinforiani E, Banchieri LM, Zucchella C, Bemasconi L, Nappi G. Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population. Funct Neurol 2003; 18: 233-237 (Pubitemid 38239687)
18. Folstein MF, Folstein SE, McHugh PR. Mini Mental State; a practical method grading the cognitive status of patients for the clinician. J Psychiatry Res 1975; 12: 189-198
19. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944 (Pubitemid 14076461)
20. Lawton MP. Scales to measure competence in everyday activities. Psychopharmacol Bull 1988; 24: 695-697
21. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186
22. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gombein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314 (Pubitemid 24382728)
23. Seltzer B. Is long-term treatment of Alzheimer's disease with Cholinesterase inhibitor therapy justified? Drugs Aging 2007; 24: 881-890
24. Raina P, Santaguida P, Ismaila A et al. Effectiveness of Cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-387 (Pubitemid 351665469)
25. Qaseem A, Snow V, Cross T et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148: 370-378 (Pubitemid 351665468)
26. Pariente A, Helmer C, Merliere Y, Moore N, Fourrier-Réglat A, Dartigues JF. Prevalence of Cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008; 17: 655-660